Mr. Ron Nagar reports

TEMPRAMED SIGNS LOI FOR DISTRIBUTION AGREEMENT IN PANAMA, EXPANDING CENTRAL AMERICAN EXPOSURE

Tempramed Technologies Ltd. has signed a non-binding letter of intent (LOI), dated March 22, 2026, with TEM Consulting International S.A., a leading health care logistics and consultancy company based in the Panama, with respect to the distribution of the company's products.

The LOI marks the company's strategic expansion into Central America, and once signed, the distribution agreement will ensure Tempramed's VIVI product portfolio to become widely accessible to consumers across brick-and-mortar pharmacies, medical distributors and medical focused retail channels. The distribution agreement will represent the company's next step in its expansion strategy across the Americas and globally, adding to its current partnerships in Korea, Turkey, Israel and Benelux regions. A definitive agreement is expected be signed between the parties in 90 days.

TEM is recognized for import and distribution of high-quality surgical and medical disposables throughout Panama, operating within both the health care supply chain and the wider commercial landscape. Through its extensive nationwide reach across hospitals, clinics and pharmacy networks throughout the country, TEM will ensure the efficient and scalable introduction of Tempramed's product portfolio across the country.

Tempramed has a portfolio of temperature regulated products for many variations of injectable medications and will continue to launch new versions into the market. This partnership will enable health care professionals, pharmacies and patients to access Tempramed's patented technology, designed to maintain medication safety and efficacy in everyday life, travel and changing climate conditions.

"We are thrilled this potential collaboration with TEM, whose deep expertise in health care logistics and omnichannel distribution aligns perfectly with our global growth strategy," said Ron Nagar, chief executive officer of Tempramed. "We are seeing significant demand and a growing need for the products we offer, especially in areas like Central America, where diabetes and obesity are on the rise. Having such partner in Central America marks an important step in our broader expansion globally. Together with TEM, we look forward to building a long-term partnership that will accelerate access to Tempramed's innovative solutions across America and beyond."

Access in a growing market

In Panama, the International Diabetes Foundation estimates 312,800 adults aged 20 to 79 with diabetes in 2024, equal to 11.1-per-cent age-standardized prevalence, rising to 490,800 by 2050. On the weight-management side, the World Obesity Federation shows about 29.9-per-cent adult obesity prevalence and roughly 73.9 per cent combined overweight/obesity prevalence. While insulin is available in the public system through Panama's Social Security Fund with monthly spend of $50 (U.S.) to $160 (U.S.) (regular/analogue) insulin, GLP-1 use in Panama is largely private-pay/out-of-pocket today with a monthly spend of $240 (U.S.) to $400 (U.S.). Given these numbers, the potential market for the company's products is expected to be in urban, higher-income private-pay patients to begin with.

About TEM Consulting International S.A.

Since 2014, TEM Consulting International has established itself as a premier Panamanian specialist in the import and distribution of high-quality surgical and medical disposables. With proven expertise in government tenders and as a key partner to Panama's public and private health care systems -- including the Caja de Seguro Social and Ministerio de Salud -- TEM provides extensive nationwide reach across hospitals, clinics and pharmacy networks throughout the country.

TEM maintains strategic distribution agreements with leading international manufacturers such as Dynarex (a leader in disposable medical supplies), Medline, MedPride, Reach Surgical, Texpol, IHT and Prim, ensuring a diversified portfolio of trusted global brands. By leveraging Panama City's strategic role as a global logistical gateway and its established distribution network with nationwide delivery capabilities, TEM offers a high-value platform for international suppliers to successfully enter, scale rapidly and access proven demand within the growing Latin American health care market.

About Tempramed Technologies Ltd.

Tempramed Technologies is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, Food and Drug Administration-registered, thermal insulation devices that work 24/seven without batteries or external power. With a product line already in market including VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe and Asia, Tempramed will continue to expand globally offering a solution for medication protection and adherence.

We seek Safe Harbor.